TrialSpark is rebranding to Formation Bio, effective December 5, 2023. Click here to learn more.

Talk to your patients about the Alzheimer's Disease study

A clinical trial near you is evaluating an investigational medication to determine if it is safe and effective in reducing agitation symptoms in patients with Alzheimer’s Disease.

  • Drug IP

    Joining a clinical trial may provide options.

  • SAN-PHY-001 - Right Side List Logo Media

    Potential to advance medical research for Alzheimer’s Disease.

  • Money

    Patients may get reimbursed for study-required travel.

What is the purpose of the study?

Agitation, among other symptoms associated with Alzheimer's Disease, can be difficult to manage. This clinical trial, Sunrise, is investigating a study medication to determine if it is safe and effective in reducing agitation symptoms in patients with Alzheimer's Disease.

Visit the official U.S. clinical trials website to learn more

How to connect your patients to the study

  1. Speak with Patients and Caregivers

    Speak with patients and their caregivers about the study and provide them with Patient & Caregiver Information document.

  2. Share Link to Prescreening Questionnaire

    Instruct caregivers to go to and complete the Patient Application Form

  3. TrialSpark Connects with Qualified Patients

    A TrialSpark Nurse Enrollment Specialist will connect with qualified patients and caregivers to further assess potential eligibility before scheduling patients for a screening appointment at the study site.

What Patients can Expect in The Study

  1. Screening (4 weeks) A potential research volunteer will have the opportunity to review the consent document fully to make an educated decision about whether to participate in the trial. Upon consent, the study doctor will perform assessments to confirm that a patient is eligible to participate. Enrolled participants will be randomly assigned either the investigational medication or the placebo.

  2. Study Treatment Period (6 weeks) The study medication being investigated is an oral medication taken every night to see if it potentially reduces agitation symptoms in individuals with Alzheimer's Disease. To monitor safety and study progress, certain study visits will include: collecting medical history information, physician exams, behavioral / psychiatric questionnaires, blood draws, and electrocardiograms (ECGs).

  3. Follow-up (2 weeks) After treatment ends, the study doctor will continue to follow up with the participant. During the last visit of the follow-up period, the participant's safety will be thoroughly monitored and evaluated.

7 visits

There are 7 total study visits, 6 in person and 1 remote. Of the 6 in person visits, 2 can also be conducted remotely if preferred.

12 weeks

The 7 study visits will be scheduled over a period of about 12 weeks.

1x / night

The study medication is an oral medication that will be taken once daily at bedtime.

Start referring your patients to the Sunrise Alzheimer’s Disease study today!

Express your interest in a clinical trial today.